ライフサイエンスコーパス: coronary stent

1 months after randomization (33 months after coronary stenting).

2 results in reducing restenosis recurrence in coronary stents.

3 nd drug used in the CYPHER Sirolimus-eluting Coronary Stents.

4 Of these procedures, 57.7% involved coronary stents.

5 y; 1,120 (4.6%) cases involved patients with coronary stents.

6 ituted for ticlopidine in patients receiving coronary stents.

7 idine with clopidogrel in patients receiving coronary stents.

8 rior myocardial infarction (MI) treated with coronary stents.

9 nclusive population of subjects treated with coronary stents.

10 hy (CTA) improves diagnostic performance for coronary stents.

11 clopidogrel is widely used in patients with coronary stents.

12 nary structures such as coronary plaques and coronary stents.

13 Acute occlusion appears to require coronary stenting.

14 : coronary-artery bypass grafting (CABG) and coronary stenting.

15 dromes and as prevention of thrombosis after coronary stenting.

16 the settings of acute coronary syndromes and coronary stenting.

17 sed risk for recurrent ischemic events after coronary stenting.

18 pirin-sensitive patients undergoing elective coronary stenting.

19 or use of distal protection during extensive coronary stenting.

20 d for clopidogrel administration in elective coronary stenting.

21 y versus balloon angioplasty with or without coronary stenting.

22 leeding events occurring beyond 1 year after coronary stenting.

23 ogrel occurs in patients undergoing elective coronary stenting.

24 LST is a potentially fatal complication of coronary stenting.

25 us coronary intervention (PCI) in the era of coronary stenting.

26 16 may be useful to prevent restenosis after coronary stenting.

27 to millions of patients worldwide following coronary stenting.

28 telet Therapy) study enrolled patients after coronary stenting.

29 atheroma burden and neointimal growth after coronary stenting.

30 atheroma burden and neointimal growth after coronary stenting.

31 morbidity and mortality, even in the era of coronary stenting.

32 igh risk for recurrent ischemic events after coronary stenting.

33 of 2 microg/kg per min) during percutaneous coronary stenting.

34 ve antiplatelet therapy given at the time of coronary stenting.

35 tients with normal or lower CK-MB rise after coronary stenting.

36 neointimal proliferation after overexpansion coronary stenting.

37 based on a perceived "suboptimal" result of coronary stenting.

38 prevention of thrombotic complications after coronary stenting.

39 and either ticlopidine or clopidogrel during coronary stenting.

40 12 months of dual antiplatelet therapy after coronary stenting.

41 is (ST) in stable patients with a history of coronary stenting.

42 sis (ST) is a serious complication following coronary stenting.

43 MI) and coronary revascularization following coronary stenting.

44 gery should be delayed until 12 months after coronary stenting.

45 evidence exists on sex-based outcomes after coronary stenting.

46 Patients had an average of 2.5 +/- 1.8 coronary stents (1 to 10), with a diameter of 3.0 +/- 0.

47 259 consecutive patients undergoing elective coronary stenting; 120 were on chronic clopidogrel thera

48 Four coronary stents (2, 3, 4, and 5 mm) were examined at 64-

49 ion (>1 to 5 times normal) is frequent after coronary stenting (26%), this was not associated with an

50 12,844 patients received at least one coronary stent; 5743 received only drug-eluting stents,

51 e and contrast-enhanced MRI after successful coronary stenting; 9 patients had procedure-related CK-M

52 rs of age with acute MI and AF who underwent coronary stenting (Acute Coronary Treatment and Interven

53 ry disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesi

54 platelet reactivity has been reported after coronary stenting after clopidogrel therapy and may be a

55 ified all patients who received at least one coronary stent and dual antiplatelet therapy (aspirin an

56 te coronary syndrome (ACS) or treated with a coronary stent and receiving a thienopyridine awaiting C

57 n diabetics treated with a sirolimus-eluting coronary stent and suggest a potential novel therapeutic

58 y assigned 11 648 patients who had undergone coronary stenting and completed 1 year of dual antiplate

59 Individuals who underwent coronary stenting and completed 12 months of thienopyrid

60 rovement in timely access to clopidogrel for coronary stenting and improved cardiovascular outcomes.

61 er these standards remain valid when routine coronary stenting and newer pharmacological agents are u

62 When used in combination with PTCA, coronary stenting and platelet glycoprotein IIb/IIIa inh

63 niformly determine platelet reactivity after coronary stenting and treatment strategies to improve P2

64 onsisted of 2 groups: patients who underwent coronary stenting and were treated with ticlopidine and

65 es are frequently performed in patients with coronary stents and are associated with an increased ris

66 Surgery is frequent in patients with coronary stents and carries a considerable risk of ische

67 arch was conducted before the routine use of coronary stents and thienopyridines.

68 Studies did not include coronary stenting, and results should not be applied to

69 dial infarction, and cardiac mortality after coronary stenting, and the long-term safety of drug-elut

70 published studies suggest that patients with coronary stents, and in particular those with drug-eluti

71 e, acute coronary syndrome presentation, and coronary stenting appears strongly predictive of 30-day

72 rly cardiovascular and bleeding events after coronary stenting are associated with high risk of morbi

73 We tested whether paclitaxel-coated coronary stents are effective at preventing neointimal p

74 and consequences of surgery in patients with coronary stents are not clearly defined, as well as the

75 and angiographic consequences of overlapped coronary stents are not clearly defined, particularly fo

76 increasing number of patients have received coronary stents as a treatment for coronary artery disea

77 has decreased nationally, whereas the use of coronary stents as an alternative has grown tremendously

78 tion monitoring and treatment adjustment for coronary stenting, as compared with standard antiplatele

79 r analysis if they had received at least one coronary stent at the time of the index procedure follow

80 andomly assigned 2440 patients scheduled for coronary stenting at 38 centers to a strategy of platele

81 ospective cohort study of patients receiving coronary stents at Veterans Affairs medical centers betw

82 tly to the abluminal surface of a bare metal coronary stent, at a dose density of 2.7 microg/mm2, red

83 complications in patients who have undergone coronary stenting before a noncardiac surgery have not b

84 12 inhibitor prevents ischaemic events after coronary stenting, but increases bleeding.

85 pidogrel with aspirin for up to 1 year after coronary stenting, but the value of clopidogrel beyond t

86 rs the opportunity to improve outcomes after coronary stenting by individualizing therapy.

87 ated prospectively among 5,850 patients from coronary stent clinical trials.

88 istribution of pharmaceutical molecules in a coronary stent coating and are used to visualize the dru

89 The coronary stent coating consists of 25% (w/w) sirolimus i

90 g-term costs and cost-effectiveness (C/E) of coronary stenting compared with primary balloon angiopla

91 This study suggests that coronary stenting, compared with balloon procedures, red

92 gated the safety and efficacy of V-Flex Plus coronary stents (Cook Inc) coated with escalating doses

93 e Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) study demonstrated that

94 Morphology after coronary stenting demonstrates early thrombus formation

95 Coronary stent deployment is associated with a low incid

96 nts with isolated coronary lesions underwent coronary stent deployment starting at 10 atm and increas

97 atment of acute coronary syndromes and after coronary stent deployment.

98 u PT enrolled 80 patients undergoing de novo coronary stent deployment.

99 clopidogrel compared with ticlopidine after coronary stent deployment.

100 First-generation drug-eluting coronary stents (DES) were introduced in 2003 to 2004, a

101 are at high risk for ischemic outcomes after coronary stenting, despite IIb/IIIa inhibition.

102 se of the sirolimus (rapamycin) drug-eluting coronary stent, diabetics are at increased risk of devel

103 Coronary stents, drug-eluting stents in particular, have

104 , and an additional 449 patients receiving a coronary stent during the trial (total 14,491).

105 Among 39 362 patients with previous coronary stenting enrolled in a multicenter prospective

106 nts (6219 treated vessels) treated with >/=1 coronary stent followed by antiplatelet therapy with asp

107 A group, n=1406), and patients who underwent coronary stenting followed by treatment with clopidogrel

108 Coronary stenting for CAV is hampered by ISR.

109 We analyzed 1,362 patients undergoing coronary stenting for PPCP, procedural and in-hospital e

110 Patients were followed for 1 year after coronary stenting for the occurrence of death, myocardia

111 Medicare patients who underwent nonemergent coronary stenting from October 2002 through March 2003 w

112 t) and 28,086 similar patients who underwent coronary stenting from September through December 2003,

113 Histomorphometry was performed on coronary stents from 127 patients (171 lesions) who died

114 Despite the routine use of high pressure, coronary stents generally fail to achieve a cross-sectio

115 at patients with CK-MB >5 times normal after coronary stenting had an increased risk of major adverse

116 Over the past decade, coronary stenting has emerged as the dominant form of pe

117 Long-term follow-up of patients after coronary stenting has identified stent thrombosis as a r

118 ing both the early and late complications of coronary stenting has not previously been explored.

119 ient outcomes, but whether implementation of coronary stents has allowed low-volume physicians and ce

120 CTA of coronary stents has been limited by nondiagnostic studie

121 and its safety as a pharmacologic adjunct to coronary stenting have not been well described.

122 importance of cardiac enzyme elevation after coronary stenting have not been well established.

123 major contributions to patient welfare, and coronary stents have been among the most important devic

124 Bioresorbable coronary stents have been introduced into clinical pract

125 Improvements in coronary stents have led some to advocate percutaneous c

126 Although most clinical trials of coronary stents have measured nominally identical safety

127 s the independent relationship between prior coronary stent implantation and the occurrence of periop

128 e hundred nine patients underwent successful coronary stent implantation and were treated with dual a

129 in patients undergoing otherwise uneventful coronary stent implantation as well as in the overall st

130 reducing ischemic complications of nonurgent coronary stent implantation at 48 hours and at 30 days.

131 zed, with 14,042 (53%) having a history of a coronary stent implantation before randomization, and an

132 target lesion revascularization [TLR]) after coronary stent implantation has been incompletely evalua

133 This study found that prior coronary stent implantation is an independent risk facto

134 e site-specific delivery of paclitaxel after coronary stent implantation is highly effective in reduc

135 However, routine IVUS guidance of coronary stent implantation is not supported by a critic

136 Adjunctive eptifibatide therapy during coronary stent implantation provides benefit through 6-m

137 While coronary stent implantation reduces the need for repeat

138 ndomized 2,064 patients undergoing nonurgent coronary stent implantation to eptifibatide or placebo.

139 We assigned 705 patients who had successful coronary stent implantation to receive, in addition to a

140 9-month clinical outcomes of patients whose coronary stent implantation was suboptimal, and compared

141 Twenty-nine allergic patients who underwent coronary stent implantation were compared with a nonalle

142 tiplatelet therapy among patients undergoing coronary stent implantation with and without MI.

143 rventions, including balloon angioplasty and coronary stent implantation, are associated with increas

144 In the first year after coronary stent implantation, clinical failures are drive

145 lumen revascularization favoring IVUS-guided coronary stent implantation, it is likely that this effe

146 T) is a rare but devastating complication of coronary stent implantation, occurring in 0.5% to 1.9% o

147 nistration of clopidogrel before anticipated coronary stent implantation.

148 o be the principal cause of restenosis after coronary stent implantation.

149 (ESPRIT) trial of adjunctive eptifibatide in coronary stent implantation.

150 clopidine and aspirin in patients undergoing coronary stent implantation.

151 et therapy after acute coronary syndromes or coronary stent implantation.

152 Coronary-stent implantation is frequently performed for

153 Within 24 months of 124,844 coronary stent implantations (47.6% DES, 52.4% BMS), 28,

154 Data for patients with coronary stents implanted in a VA hospital from 2000 to

155 Coronary stents improve immediate and late results of ba

156 ne if clopidogrel treatment initiated before coronary stenting improved clinical outcomes among patie

157 ral randomized trials have demonstrated that coronary stenting improves angiographic and clinical out

158 The use of coronary stents improves the outcomes of percutaneous co

159 FD-OCT was performed before and after coronary stenting in 50 patients undergoing percutaneous

160 nction testing did not improve outcome after coronary stenting in the Assessment by a Double Randomiz

161 DS (United States Renal Data System) who had coronary stenting in the United States between April 23,

162 ths) in 70 consecutive patients treated with coronary stents in 2 (93% of patients) or 3 SVGs, as com

163 ntion (PCI) with drug-eluting and bare-metal coronary stents in acute myocardial infarction have been

164 Despite the increased use of coronary stents in humans, there are only limited pathol

165 al Comparison of the Xience V and the Cypher Coronary Stents in Non-selected Patients With Coronary H

166 Caring for patients with coronary stents in the perioperative period requires inp

167 ial therapeutic benefit of paclitaxel-coated coronary stents in the prevention and treatment of human

168 Comparison of Xience V and Multi-Link Vision Coronary Stents in the Same Multivessel Patient with Chr

169 (A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-Seg

170 fold (BRS) may have advantages over metallic coronary stents in this population.

171 ar) in 398 consecutive patients treated with coronary stents in two (94% of patients) or three native

172 Eptifibatide during nonurgent coronary stent intervention only minimally (and insignif

173 duces ischemic complications after nonurgent coronary stent interventions.

174 continued thienopyridine beyond 1 year after coronary stenting is associated with reduced risk of MI,

175 One-year success after coronary stenting is limited mainly by restenosis of and

176 Coronary stenting is not without problems and is complic

177 Their role as an adjunct to coronary stenting is still under investigation.

178 Whether routine implantation of coronary stents is the best strategy to treat flow-limit

179 PCI and outcomes still exists in the era of coronary stents is unclear.

180 tiplatelet therapy for at least 1 year after coronary stenting, ischemic events were more frequent th

181 l of 14 963 patients treated with DAPT after coronary stenting-largely consisting of aspirin and clop

182 rnative image postprocessing led to enhanced coronary stent lumen depiction to an extent beyond that

183 Parallel microgrooves on coronary stent luminal surfaces promote endothelial cell

184 In the era of coronary stents, Medicare patients treated by high-volum

185 c and angiographic restenosis in the porcine coronary stent model when delivered locally.

186 ember 1995 and June 1996 who received either coronary stent (n = 384) or coronary angioplasty (n = 15

187 ng of volunteers (n = 94) and patients after coronary stenting (n = 405), with heart failure (n = 25)

188 undergo balloon angioplasty (PTCA, n=448) or coronary stenting (n=452).

189 ere measured in patients undergoing elective coronary stenting (n=96) at baseline and at 2 hours, 24

190 Restenosis after coronary stenting necessitates repeated percutaneous or

191 itive remodeling of the vessel exterior to a coronary stent occurs to a variable degree after stent i

192 y-two domestic swine underwent overexpansion coronary stenting of 2 vessels.

193 tudy was designed to determine the effect of coronary stents on in-hospital mortality.

194 If a coronary stent or vessel was nondiagnostic on CTA, adeno

195 size is early reperfusion with percutaneous coronary stenting or thrombolytic therapy.

196 is patients in the United States after PTCA, coronary stenting, or CABG.

197 ransluminal coronary angioplasty and 33% for coronary stenting [P=0.09 for difference]).

198 mpared 30-day event rates in 500 consecutive coronary stent patients treated with aspirin and clopido

199 Based on the CK-MB levels after coronary stenting, patients were classified into three g

200 ocardial infarction (AMI) after percutaneous coronary stenting (PCS) by coregistering PET and coronar

201 CE) performed before and early after primary coronary stenting (PCS) in patients with acute myocardia

202 s at US Veterans Affairs hospitals who had a coronary stent placed between January 1, 2000, and Decem

203 Surgery in patients with a coronary stent placed for MI was associated with increas

204 After coronary stent placement and 12 months treatment with op

205 We sought to compare patient outcomes for coronary stent placement and balloon angioplasty.

206 Recent coronary stent placement and noncardiac surgery contribu

207 Magnetic resonance imaging <8 weeks after coronary stent placement appears to be safe, and the ris

208 urrent guidelines for delaying surgery after coronary stent placement are based on stent type.

209 Surgery after coronary stent placement is associated with an approxima

210 bination of rotational atherectomy and intra-coronary stent placement is between 2% and 7.5% of inter

211 Forty patients who underwent coronary stent placement less than six weeks before nonc

212 11 patients who underwent MRI <8 weeks after coronary stent placement treated with aspirin and a thie

213 Among patients undergoing coronary stent placement with aspirin and a GP IIb/IIIa

214 Among patients undergoing coronary stent placement with BMS and who tolerated 12 m

215 ergoing noncardiac surgery within 2 years of coronary stent placement, MACE were associated with emer

216 rgical procedures within 24 months following coronary stent placement, the stent indication was MI in

217 o prevent thrombotic complications following coronary stent placement.

218 derive greatest benefit from its use during coronary stent placement.

219 edian of 18 days (range, 0 to 54 days) after coronary stent placement.

220 netic resonance imaging (MRI) <8 weeks after coronary stent placement.

221 stponing MRI studies until eight weeks after coronary stent placement.

222 rge population of patients who had undergone coronary stent placement.

223 rgoing single-vessel balloon angioplasty and coronary stent placement.

224 nts were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent w

225 Over 1 million coronary stent procedures are performed annually in the

226 it has been observed in randomized trials of coronary stent procedures compared with medical therapy

227 elaying noncardiac surgery in patients after coronary stent procedures for 1 year after drug-eluting

228 Paclitaxel-coated coronary stents produced a significant dose-dependent in

229 ular events, when compared with a bare metal coronary stent prosthesis.

230 In contemporary practice, coronary stenting provides equivalent or better one-year

231 echanical properties of a new self-expanding coronary stent (RADIUS) and, particularly, the subsequen

232 In stable patients with coronary stenting receiving standard antiplatelet therap

233 Coronary stents reduce the rates of abrupt closure, emer

234 Previous studies have demonstrated that coronary stenting reduces clinical and angiographic rest

235 enopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) ris

236 or long-term dual-antiplatelet therapy after coronary stenting remain poorly defined.

237 late vascular remodeling after angioplasty, coronary stents remain vulnerable to restenosis, caused

238 Nonetheless, optimal outcomes after coronary stenting require careful attention to antithrom

239 The ECM within human coronary stents resembles a wound that is not fully heal

240 ion in a dose dependent fashion in a porcine coronary stent restenosis model, while allowing for comp

241 Coronary stents result in large lumens with "room" to ac

242 ncardiac surgery for two to four weeks after coronary stenting should permit completion of the mandat

243 Coronary stenting (STENT) and left internal mammary arte

244 f LST were selected from a registry of human coronary stents submitted for analysis.

245 ss all the limitations of permanent metallic coronary stents, such as the risks of target lesion reva

246 rt of ticlopidine-treated patients following coronary stenting suggests that TTP occurs much more com

247 of the Evolution Everolimus-Eluting Monorail Coronary Stent System [Evolution Stent System] for the T

248 Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coron

249 valuation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With

250 valuation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with

251 valuation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With

252 valuation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial at 1 year were sustained

253 valuation of the XIENCE V Everolimus Eluting Coronary Stent System) trial.

254 Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) Workhorse (WH) trial is a prospec

255 Coronary stenting that is accompanied by medial damage o

256 In patients who received coronary stents, the CABG rate was 1.20% vs 2.78% for pa

257 treatment with vorapaxar reduces the rate of coronary stent thrombosis (ST) in stable patients with a

258 The risk of coronary stent thrombosis from dislodgement due to MRI e

259 ents or dual antiplatelet therapy to prevent coronary stent thrombosis have generally had narrow incl

260 Perioperative coronary stent thrombosis is a catastrophic complication

261 on the type and urgency of surgery, type of coronary stent, time since the coronary intervention and

262 ARCTIC, 2440 patients were randomized before coronary stenting to a strategy of platelet function mon

263 randomized 300 patients undergoing elective coronary stenting to loading with clopidogrel 600 mg, pr

264 al antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, y

265 nded standard of care for patients receiving coronary stents to prevent thrombosis.

266 Six recently completed coronary stent trials and associated nonrandomized regis

267 periprocedural myocardial infarction (MI) in coronary stent trials has not been established.

268 Patient-level data from 3 contemporary coronary stent trials were pooled by an independent acad

269 stents as part of pivotal second-generation coronary stent trials.

270 ions) pooled from several recently completed coronary stent trials.

271 ticism by analyzing a sample of contemporary coronary stent trials.

272 ent of antiplatelet therapy in patients with coronary stents undergoing cardiac and noncardiac surger

273 ative cardiovascular events in patients with coronary stents undergoing noncardiac surgery (NCS).

274 tenosis of a previously implanted bare-metal coronary stent (vessel diameter, 2.5-3.75 mm; lesion len

275 A coronary stent was placed in 77% of procedures, but this

276 antiplatelet therapy beyond 12 months after coronary stenting was associated with an unexpected incr

277 erall rate of 30-day events in patients with coronary stents was 2.1% (n=170).

278 g internal mammary artery (IMA) grafting +/- coronary stenting were compared with a matched group of

279 s older than 18 years with an indication for coronary stenting were enrolled, and 11648 (mean age, 61

280 e methodologic characteristics of studies in coronary stenting were extracted and summarized accordin

281 ogrel with ticlopidine in patients receiving coronary stents were pooled, and a formal meta-analysis

282 evant end points pertaining to the safety of coronary stents, which have not been compared among biod

283 es among 875 consecutive patients undergoing coronary stenting who received adjunctive aspirin and ei

284 Patients receiving coronary stents who require warfarin are at high risk fo

285 agonists, low molecular weight heparins, and coronary stents will be directed toward these high risk

286 tiplatelet and anticoagulant agents, and new coronary stents will continue the journey to achieve thi

287 Enhanced designs of new coronary stents will continue to expand the spectrum of

288 y and efficacy of a novel cobalt alloy-based coronary stent with a durable elastomeric polymer elutin

289 We report preliminary experience using a new coronary stent with programmable pharmacokinetics.

290 bosis are potentially fatal complications of coronary stenting with a recognized multifactorial etiol

291 Coronary stenting with abciximab, compared with stenting

292 al and long-term clinical outcomes of direct coronary stenting with balloon predilation followed by s

293 Subjects undergoing coronary stenting with complex lesion anatomy may experi

294 elet function testing in patients undergoing coronary stenting with further therapeutic adjustment do

295 ociated with adverse clinical outcomes after coronary stenting with glycoprotein IIb/IIIa inhibition.

296 e and one year medical costs and outcomes of coronary stenting with those for balloon angioplasty (pe

297 d veteran taking clopidogrel and aspirin for coronary stents with significant cardiopulmonary comorbi

298 , Canada between 2003 and 2009, and received coronary stents within 10 years before surgery.

299 In contemporary coronary stenting, women have a slightly higher procedur

300 outcomes, and safety of zotarolimus-eluting coronary stents (ZES) with a phosphorylcholine polymer v